The Catholic University of Korea, Bucheon St. Mary's Hospital
Welcome,         Profile    Billing    Logout  
 19 Trials 
19 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Yong Sik
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
11/25
10/26
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
Kim, Sung Soo
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT03062059: The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence

Recruiting
2
134
RoW
Intravesical 2000mg/52.6ml gemcitabine instillation, Gem Tan inj (liquid), Normal saline
National Cancer Center, Korea, Samsung Medical Center, Asan Medical Center, Seoul National University Hospital, Korea University Anam Hospital, Chong Kun Dang Pharmaceutical Corp.
Urothelial Carcinoma
12/22
12/22
ERTEMIS, NCT05540587: Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Recruiting
2
240
RoW
Edoxaban, Warfarin
Sung-Hwan Kim, Daiichi Sankyo Korea Co., Ltd.
Mitral Valve Stenosis, Atrial Fibrillation, Stroke, Systemic Embolism
05/24
05/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
SHR-A2009-I-101, NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Recruiting
1
132
Japan, RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/23
12/24
JAGUAR, NCT05064540: Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

Recruiting
N/A
450
US
Alto Abdominal Stent Graft System, FDA Approved EVAR AAA Graft Systems
Endologix
AAA, AAA - Abdominal Aortic Aneurysm
12/28
12/28
Yoo, Hongseok
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
07/25
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
Pharmaceutical, Daewoong
NCT05389215: Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Recruiting
2
102
US, RoW
DWN12088, DWN12088 Xmg Tablet (BID), Placebo, Placebo 0mg Tablet (BID)
Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis
09/25
12/25

Download Options